特异性促炎症消退介质在银屑病中的研究进展

doi:10.35541/cjd.20240503

中华皮肤科杂志 ›› 2025, e0240503.doi: 10.35541/cjd.20240503

• 综述 • 上一篇

特异性促炎症消退介质在银屑病中的研究进展

黄淑黛¹ 周栩悦² 张家安² 陈崑²

¹北京协和医学院中国医学科学院皮肤病医院皮肤病研究所，南京 210042；²中国医学科学院北京协和医学院皮肤病医院理疗科，南京 210042

收稿日期:2024-09-20 修回日期:2024-12-26 发布日期:2025-09-09
通讯作者: 陈崑 E-mail:kunchen181@aliyun.com
基金资助:
国家自然科学基金项目（82273552，82203947，82304049）；江苏省自然科学基金项目（BK20220214）；中国医学科学院医学科学创新基金项目（CIFMS 2021-I2M-1-001）；北京协和医学院“中央高校基本科研业务费”项目（3332023172）

Role of specialized pro-resolving mediators in psoriasis

Huang Shudai¹, Zhou Xuyue², Zhang Jiaan², Chen Kun²

¹Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China; ²Department of Physical Therapy, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences ＆ Peking Union Medical College, Nanjing 210042, China

Received:2024-09-20 Revised:2024-12-26 Published:2025-09-09
Contact: Chen Kun E-mail:kunchen181@aliyun.com
Supported by:
National Natural Science Foundation of China （82273552, 82203947, 82304049）; Natural Science Foundation of Jiangsu Province （BK20220214）; CAMS Innovation Fund for Medical Sciences （CIFMS 2021-I2M-1-001）; Fundamental Research Funds for Central Universities in PUMC （3332023172）

摘要/Abstract

摘要： 【摘要】银屑病是一种以T淋巴细胞异常活化和角质形成细胞过度增生为特征的慢性炎症性皮肤病，而持续的炎症反应是银屑病的核心病理过程。特异性促炎症消退介质可通过多种机制抑制炎症反应，并能够主动促进炎症的消退，其对炎症的双重调控作用在银屑病发病机制研究中也受到了关注。本文旨在综述特异性促炎症消退介质的最新研究进展，探讨其在银屑病中的具体作用及潜在的临床应用价值。

关键词: 银屑病, 脂肪酸类, 不饱和, 脂氧素类, 特异性促炎症消退介质, 治疗, 炎症介导素类

Abstract: 【Abstract】 Psoriasis is a chronic inflammatory skin disorder characterized by aberrant activation of T lymphocytes and excessive proliferation of keratinocytes, with persistent inflammation being the central pathological feature. Specialized pro-resolving mediators （SPMs） exert anti-inflammatory effects through various mechanisms, actively facilitating the resolution of inflammation. The dual regulatory role in inflammation has garnered attention in the study of psoriasis pathogenesis. This review aims to consolidate recent advancements in SPMs, explore their specific roles in psoriasis pathogenesis, and evaluate their potential clinical application.

Key words: Psoriasis, Fatty acids, unsaturated, Lipoxins, Specialized pro-resolving mediators, Therapy, Inflammation mediators

黄淑黛周栩悦张家安陈崑. 特异性促炎症消退介质在银屑病中的研究进展[J]. 中华皮肤科杂志, 2025,e0240503. doi:10.35541/cjd.20240503

Huang Shudai, Zhou Xuyue, Zhang Jiaan, Chen Kun. Role of specialized pro-resolving mediators in psoriasis[J]. Chinese Journal of Dermatology,2025,e0240503. doi:10.35541/cjd.20240503

参考文献 37

［1］	Fredman G, Serhan CN. Specialized pro⁃resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease［J］. Nat Rev Cardiol, 2024,21（11）:808⁃823. doi: 10.1038/s41569⁃023⁃00984⁃x.
［2］	Wang X, Ma R, Shi R, et al. Sex differences in the association between plasma polyunsaturated fatty acids levels and moderate⁃to⁃severe plaque psoriasis severity: a cross⁃sectional and longitudinal study［J］. J Transl Med, 2023,21（1）:834. doi: 10. 1186/s12967⁃023⁃04726⁃y.
［3］	Merlin J, Park J, Vandekolk TH, et al. Multipathway in vitro pharmacological characterization of specialized proresolving G protein⁃coupled receptors［J］. Mol Pharmacol, 2022,101（4）:246⁃256. doi: 10.1124/molpharm.121.000422.
［4］	Hu F, Qu Z, Chen K, et al. Lipoxin A4 ameliorates imiquimod⁃induced psoriasis⁃like dermatitis via promoting the regression of inflammation［J］. Clin Cosmet Investig Dermatol, 2023,16:2103⁃2111. doi: 10.2147/CCID.S418467.
［5］	Schottelius AJ, Giesen C, Asadullah K, et al. An aspirin⁃triggered lipoxin A4 stable analog displays a unique topical anti⁃inflammatory profile［J］. J Immunol, 2002,169（12）:7063⁃7070. doi: 10.4049/jimmunol.169.12.7063.
［6］	Brown AL. And the germline beat （AML） goes on［J］. Blood, 2022,139（8）:1126⁃1128. doi: 10.1182/blood.2021013771.
［7］	Gao J, Su Y, Wang Z. Lung inflammation resolution by RvD1 and RvD2 in a receptor⁃dependent manner［J］. Pharmaceutics, 2023,15（5）:1527. doi: 10.3390/pharmaceutics15051527.
［8］	Campbell EL, Louis NA, Tomassetti SE, et al. Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution［J］. FASEB J, 2007,21（12）:3162⁃3170. doi: 10.1096/fj.07⁃8473com.
［9］	Liang Z, Yue H, Xu C, et al. Protectin DX relieve hyperoxia⁃induced lung injury by protecting pulmonary endothelial glycocalyx［J］. J Inflamm Res, 2023,16:421⁃431. doi: 10.2147/JIR.S391765.
［10］	Chen O, Donnelly CR, Ji RR. Regulation of pain by neuro⁃immune interactions between macrophages and nociceptor sensory neurons［J］. Curr Opin Neurobiol, 2020,62:17⁃25. doi: 10.1016/j.conb.2019.11.006.
［11］	Belayev L, Hong SH, Menghani H, et al. Docosanoids promote neurogenesis and angiogenesis, blood⁃brain barrier integrity, penumbra protection, and neurobehavioral recovery after experimental ischemic stroke［J］. Mol Neurobiol, 2018,55（8）:7090⁃7106. doi: 10.1007/s12035⁃018⁃1136⁃3.
［12］	Leroy V, Cai J, Filiberto A, et al. Resolution of post⁃lung transplant ischemia⁃reperfusion injury is mediated via resolvin D1⁃Alx/FPR2 and maresin 1⁃LGR6 receptor signaling［J］. The Journal of Heart and Lung Transplantation, 2021,40（4）:s55⁃s56. doi:10.1016/j.healun.2021.01.1876.
［13］	Chiang N, Libreros S, Norris PC, et al. Maresin 1 activates LGR6 receptor promoting phagocyte immunoresolvent functions［J］. J Clin Invest, 2023,133（2）:e168084. doi: 10.1172/JCI168084.
［14］	Sun S, Wang L, Wang J, et al. Maresin1 prevents sepsis⁃induced acute liver injury by suppressing NF⁃κB/Stat3/MAPK pathways, mitigating inflammation［J］. Heliyon, 2023,9（11）:e21883. doi: 10.1016/j.heliyon.2023.e21883.
［15］	Saito⁃Sasaki N, Sawada Y, Mashima E, et al. Maresin⁃1 suppresses imiquimod⁃induced skin inflammation by regulating IL⁃23 receptor expression［J］. Sci Rep, 2018,8（1）:5522. doi: 10.1038/s41598⁃018⁃23623⁃9.
［16］	Xu J, Duan X, Hu F, et al. Resolvin D1 attenuates imiquimod⁃induced mice psoriasiform dermatitis through MAPKs and NF⁃κB pathways［J］. J Dermatol Sci, 2018,89（2）:127⁃135. doi: 10. 1016/j.jdermsci.2017.10.016.
［17］	Sawada Y, Honda T, Nakamizo S, et al. Resolvin E1 attenuates murine psoriatic dermatitis［J］. Sci Rep, 2018,8（1）:11873. doi: 10.1038/s41598⁃018⁃30373⁃1.
［18］	Park KD, Kim N, Kang J, et al. Protectin D1 reduces imiquimod⁃induced psoriasiform skin inflammation［J］. Int Immunopharmacol, 2021,98:107883. doi: 10.1016/j.intimp.2021.107883.
［19］	Yuan J, Lin F, Chen L, et al. Lipoxin A4 regulates M1/M2 macrophage polarization via FPR2⁃IRF pathway［J］. Inflammopharmacology, 2022,30（2）:487⁃498. doi: 10.1007/s10787⁃022⁃00942⁃y.
［20］	Maderna P, Cottell DC, Toivonen T, et al. FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin⁃derived peptide⁃stimulated phagocytosis［J］. FASEB J, 2010,24（11）:4240⁃4249. doi: 10.1096/fj.10⁃159913.
［21］	Hu F, Liu XX, Wang X, et al. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes associated with the ERK1/2 and NF⁃κB pathways［J］. J Dermatol Sci, 2015,78（3）:181⁃188. doi: 10.1016/j.jdermsci.2015.03.009.
［22］	Kelly AG, Panigrahy D. Targeting angiogenesis via resolution of inflammation［J］. Cold Spring Harb Perspect Med, 2023,13（3）:a041172. doi: 10.1101/cshperspect.a041172.
［23］	Laban A, Atallah R, Eldahshan R, et al. Assessment of retinal vasculature in patients with psoriasis［J］. International Journal of Medical Arts, 2022,4（11）:2767⁃2774. doi:10.21608/ijma.2023. 176787.1560.
［24］	Sun W, Ma J, Zhao H, et al. Resolvin D1 suppresses pannus formation via decreasing connective tissue growth factor caused by upregulation of miRNA⁃146a⁃5p in rheumatoid arthritis［J］. Arthritis Res Ther, 2020,22（1）:61. doi: 10.1186/s13075⁃020⁃2133⁃2.
［25］	Rajasagi NK, Reddy PB, Suryawanshi A, et al. Controlling herpes simplex virus⁃induced ocular inflammatory lesions with the lipid⁃derived mediator resolvin E1［J］. J Immunol, 2011,186（3）:1735⁃1746. doi: 10.4049/jimmunol.1003456.
［26］	Sorokin AV, Arnardottir H, Svirydava M, et al. Comparison of the dietary omega⁃3 fatty acids impact on murine psoriasis⁃like skin inflammation and associated lipid dysfunction［J］. J Nutr Biochem, 2023,117:109348. doi: 10.1016/j.jnutbio.2023.109348.
［27］	Morin S, Simard M, Rioux G, et al. Alpha⁃linolenic acid modulates T cell incorporation in a 3D tissue⁃engineered psoriatic skin model［J］. Cells, 2022,11（9）:1513. doi: 10.3390/cells11091513.
［28］	Morin S, Tremblay A, Dumais E, et al. Eicosapentaenoic acid influences the lipid profile of an in vitro psoriatic skin model produced with T cells［J］. Biomolecules, 2023,13（9）:1413. doi: 10.3390/biom13091413.
［29］	Escobar SO, Achenbach R, Iannantuono R, et al. Topical fish oil in psoriasis⁃⁃a controlled and blind study［J］. Clin Exp Dermatol, 1992,17（3）:159⁃162. doi: 10.1111/j.1365⁃2230.1992.tb00194.x.
［30］	Li N, Qin Y, Dai D, et al. Transdermal delivery of therapeutic compounds with nanotechnological approaches in psoriasis［J］. Front Bioeng Biotechnol, 2021,9:804415. doi: 10.3389/fbioe. 2021.804415.
［31］	Furutani K, Chen O, McGinnis A, et al. Novel proresolving lipid mediator mimetic 3⁃oxa⁃PD1n⁃3 docosapentaenoic acid reduces acute and chronic itch by modulating excitatory and inhibitory synaptic transmission and astroglial secretion of lipocalin⁃2 in mice［J］. Pain, 2023,164（6）:1340⁃1354. doi: 10.1097/j.pain.000 0000000002824.
［32］	Song CH, Wang R, Zhao ZK, et al. Leptin modulates the differentiation of keratinocytes via autophagy in psoriasis patients with metabolic syndrome. Int J Dermatol Venerol, 2024, 7（3）:121⁃130. doi: 10.1097/JD9.0000000000000353.
［33］	Martínez⁃Fernández L, Burgos M, Sáinz N, et al. Maresin 1 exerts a tissue⁃specific regulation of adipo⁃hepato⁃myokines in diet⁃induced obese mice and modulates adipokine expression in cultured human adipocytes in basal and inflammatory conditions［J］. Biomolecules, 2023,13（6）:919. doi: 10.3390/biom13060919.
［34］	Salazar J, Pirela D, Nava M, et al. Specialized proresolving lipid mediators: a potential therapeutic target for atherosclerosis［J］. Int J Mol Sci, 2022,23（6）:3133. doi: 10.3390/ijms23063133.
［35］	Yang WS, Wang JL, Wu W, et al. Formyl peptide receptor 2 as a potential therapeutic target for inflammatory bowel disease［J］. Acta Pharmacol Sin, 2023,44（1）:19⁃31. doi: 10.1038/s41401⁃022⁃00944⁃0.
［36］	Byrne L, Guiry PJ. Advances in the chemistry and biology of specialised pro⁃resolving mediators （SPMs）［J］. Molecules, 2024,29（10）:2233. doi: 10.3390/molecules29102233.
［37］	Rahman M, Akhter S, Ahmad J, et al. Nanomedicine⁃based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy［J］. Expert Opin Drug Deliv, 2015,12（4）:635⁃652. doi: 10.1517/17425247.2015.982088.

[1]	周妙妮盛安琪傅丽芳金嵘许文尉晓冬许爱娥. 茶多酚抗氧化凝胶联合窄谱中波紫外线治疗白癜风的疗效及安全性单中心随机对照试验[J]. 中华皮肤科杂志, 2025, 58(9): 834-838.
[2]	戴叶芹宋秀祖. 毛囊及毛囊细胞移植在白癜风治疗中的应用进展[J]. 中华皮肤科杂志, 2025, 58(9): 882-885.
[3]	徐中奕邢小雪董雅琦张成锋项蕾红. 上海市某三甲医院黄褐斑患者254例临床特征及疗效的回顾性分析[J]. 中华皮肤科杂志, 2025, 58(9): 808-815.
[4]	姜子琪钟菊丹陈廷巧陈瑾. 黄褐斑发病机制及治疗研究进展[J]. 中华皮肤科杂志, 2025, 58(9): 868-872.
[5]	钟洁敏李薇张淑娟杨艳薛如君李欣怡柯娅楠陈晓吟陈荃. 纳米微针与超声波导入氨甲环酸治疗黄褐斑的疗效与安全性比较：一项随机对照研究[J]. 中华皮肤科杂志, 2025, 58(9): 829-833.
[6]	朱婷婷, 李蔚然潘召兵刘昊唐先发朱才红黄鹤群段大威张若晨陈小建汪洋薛倩张菊锐杨丽婧张学军, 黄贺, 张博, . 巴瑞替尼联合芦可替尼乳膏治疗6例进展期非节段型白癜风患者的疗效观察[J]. 中华皮肤科杂志, 2025, 58(9): 856-859.
[7]	罗帅寒天龙海陆前进. 2024年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2025, 58(8): 777-780.
[8]	薛珂陈佳李斌. 系统性红斑狼疮靶向治疗研究进展[J]. 中华皮肤科杂志, 2025, 58(8): 781-784.
[9]	中国医师协会皮肤科医师分会痤疮学组中国研究型医院学会皮肤科学专业委员会中国中西医结合学会皮肤性病专业委员会痤疮学组. [开放获取] 寻常痤疮临床严重度分级及疗效评价中国专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(8): 709-714.
[10]	陆前进曹淑梅蒋娇. 红斑狼疮研究的现状与挑战[J]. 中华皮肤科杂志, 2025, 58(8): 715-728.
[11]	柏琪朱明芳邬清婷姬孝天杨慧怡马莉苹周佳欣. 青藤碱对DNCB诱导的特应性皮炎样模型小鼠皮损改善的作用研究[J]. 中华皮肤科杂志, 2025, 58(8): 759-766.
[12]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. [开放获取] 局限性硬皮病诊疗专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(8): 699-708.
[13]	林尽染梁晓进刘庆梅吴文育. 雄激素性秃发与代谢综合征的关联：从发病机制到治疗策略[J]. 中华皮肤科杂志, 2025, 58(7): 591-594.
[14]	吕书影王英林文君杨顶权. 联合托法替布治疗21例匐行性斑秃回顾性分析[J]. 中华皮肤科杂志, 2025, 58(7): 630-635.
[15]	王琴林尽染刘庆梅吴文育. 口服米诺地尔在斑秃治疗中的应用[J]. 中华皮肤科杂志, 2025, 58(7): 653-656.

特异性促炎症消退介质在银屑病中的研究进展

Role of specialized pro-resolving mediators in psoriasis

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 37

相关文章 15

Metrics

本文评价

推荐阅读 0